NEW YORK (GenomeWeb) – Targeted proteomics firm Biognosys said this week that it has licensed the Limited Proteolysis (LiP) technology developed by the lab of Swiss Federal Institute of Technology Zurich Professor Paola Picotti.

The method uses mass spec-based analyses of protein proteolysis patterns to assess structural changes on a proteome-wide scale and could be useful for applications including studies of drug binding and drug target deconvolution, said Biognosys Director and CEO Oliver Rinner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.